VIDEO: CAR T cell axi-cel drives B-cell lymphomas into remissionDecember 11, 2017Lymphoma & Plasma Cell DisordersImmuno-oncologyFollicular Lymphoma
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomasDecember 10, 2017Lymphoma & Plasma Cell DisordersImmunotherapyImmuno-oncologyFollicular Lymphoma
ASCT or novel therapies in early relapsing follicular lymphoma?November 30, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
CAR T-cells gain ground against hematologic cancersNovember 22, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
FDA approves obinutuzumab for follicular lymphomaNovember 17, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Debate: Is MRD ready for prime time in multiple myeloma?November 15, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Obinutuzumab edges out rituximab for PFS in follicular lymphomaOctober 6, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
VCR regimen showed efficacy in mantle cell and indolent lymphomasOctober 6, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
FDA grants accelerated approval to copanlisib for relapsed follicular lymphomaSeptember 20, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Biosimilar matches rituximab in large follicular lymphoma trialSeptember 12, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
FDA grants Priority Review to Gazyva for follicular lymphomaAugust 29, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Obinutuzumab-CHOP not superior to rituximab-CHOP in new DLBCLAugust 17, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
IMiD/Anti-CD20 combo induces complete responses in r/r NHLJuly 19, 2017Lymphoma & Plasma Cell DisordersImmuno-oncologyFollicular Lymphoma
Copanlisib makes inroads against relapsed/refractory follicular lymphomaJuly 11, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Tazemetostat active against follicular lymphoma with EZH2 mutationJuly 7, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
